Cadrenal Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D: Cadrenal Therapeutics CEO and Chairman Discloses Significant 23.6% Stake, Signals Strategic Review
Cadrenal Therapeutics, Inc.'s CEO and Chairman, Quang X. Pham, along with a related trust, has disclosed a combined beneficial ownership of 23.6% of the company's common stock, indicating a strong insider commitment and potential strategic initiatives.